Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.

doi:10.1038/s42003-024-06190-w

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.

Communications biology - 24 Apr 2024

Pfeifer Matthias, Brammeld Jonathan S, Price Stacey, Pilling James, Bhavsar Deepa, Farcas Anca, Bateson Jessica, Sundarrajan Anjana, Miragaia Ricardo J, Guan Nin, Arnold Stephanie, Tariq Laiba, Grondine Michael, Talbot Sarah, Guerriero Maria Lisa, O'Neill Daniel J, Young Jamie, Company Carlos, Dunn Shanade, Thorpe Hannah, Martin Matthew J, Maratea Kimberly, Barrell Daniel, Ahdesmaki Miika, Mettetal Jerome T, Brownell James, McDermott Ultan

Abstract excerpt

Most lung cancer patients with metastatic cancer eventually relapse with drug-resistant disease following treatment and EGFR mutant lung cancer is no exception. Genome-wide CRISPR screens, to either knock out or overexpress all protein-coding genes in cancer cell lines, revealed the landscape of pathways that cause resistance to the EGFR inhibitors osimertinib or gefitinib in EGFR mutant lung cancer. Among the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Clustered Regularly Interspaced Short Palindromic Repeats

Share to CRISPR-Cas Systems

Share to Gefitinib

Share to Hippo Signaling Pathway

Share to Indoles

Share to YAP-Signaling Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 38658677
DOI: 10.1038/s42003-024-06190-w
PMCID: PMC11043391

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.PMID 38658677Read ↗

CRISPR screens reveal YAP/TEAD axis as a mediator of drug-tolerant cells in EGFR-mutant NSCLC.Semantic proximity Read ↗

CRISPR Screens Reveal YAP/TEAD Axis as a Mediator of Drug-Tolerant Cells in EGFR- Mutant NSCLCSemantic proximity Read ↗

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cellsSemantic proximity Read ↗

SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR-mutant lung cancer.Semantic proximity Read ↗

Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung CancerSemantic proximity Read ↗

USP48 stabilizes YBX1 to enforce a Wnt-driven stemness circuit and osimertinib resistance in EGFR-mutant NSCLC.Semantic proximity Read ↗

Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer.Semantic proximity Read ↗

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.Semantic proximity Read ↗

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors.Semantic proximity Read ↗

Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP SignalingSemantic proximity Read ↗

Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilitiesSemantic proximity Read ↗

Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.